Effects of MG-132 treatment on AML cells.

MG-132 inhibits NF-κB activity in AML cells. (A) EMSA of 3 CD34⁺ AML specimens treated with or without 1 μM MG-132 for 6 hours. (B) RT-PCR analysis of 3 NF-κB transcriptional targets in AML CD34⁺ (left panel) or CD34⁺/38⁻ cells (right panel). CD34⁺/CD38⁻ cells were treated with or without 1 μM MG-132 for 6 hours; β-actin was used as a control. (C) Western blot analysis of phosphorylated IκBα in a control (untreated) versus MG-132–treated specimen. Cells were incubated for the indicated number of minutes (numbers above each lane) and then analyzed as described in “Materials and methods.”